Showing results (1-10 of 71) with videos related to
Sort By:
Pageof 8
Wiener Medizinische Wochenschrift (1946)|April 6, 2012
Basic principles of molecular effects of irradiationEdgar Selzer, Alexandra HebarExpert Review of Clinical Pharmacology|January 1, 2013
The impact of molecular targets in cancer drug development: major hurdles and future strategiesAlexandra Hebar, Peter Valent, Edgar SelzerPlos One|October 3, 2012
NVX-412, a new oncology drug candidate, induces S-phase arrest and DNA damage in cancer cells in a p53-independent mannerAlexandra Hebar, Barbara C Rütgen, Edgar SelzerJournal of Receptor and Signal Transduction Research|February 19, 2020
Quantitative and qualitative analysis of integrin subtype expression in melanocytes and melanoma cellsVerena Kopatz, Edgar SelzerExpert Review of Clinical Pharmacology|October 30, 2013
Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developmentsEdgar Selzer, Gabriela KornekCurrent Pharmaceutical Design|January 20, 2009
Targeted therapies in solid tumours: pinpointing the tumour's Achilles heelGabriela Kornek, Edgar SelzerWiener Medizinische Wochenschrift (1946)|June 19, 2008
[Organ sparing treatment modalities - which type of treatment for which carcinoma?]Gabriela Verena Kornek, Edgar SelzerAmerican Journal of Cancer Research|May 15, 2015
Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cellsThomas W Grunt, Alexandra Hebar, Sylvia Laffer, et al.Acta Crystallographica. Section E, Structure Reports Online|March 12, 2013
4-({(Z)-5-[(Z)-3-Eth-oxy-4-hy-droxy-benzyl-idene]-3-methyl-4-oxo-1,3-thia-zolidin-2-yl-idene}amino)-benzoic acid dimethyl-formamide monosolvatePaul Kosma, Edgar Selzer, Kurt MereiterPlos One|October 17, 2012
The Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer riskKatharina Proestling, Alexandra Hebar, Nina Pruckner, et al.Pageof 8